New combo therapy aims to boost rectal cancer survival
NCT ID NCT07113275
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding an immunotherapy drug (HLX10) to standard chemotherapy and radiation before surgery improves outcomes for people with locally advanced rectal cancer. It compares short-course versus long-course radiation, both followed by immunotherapy and chemotherapy. The study aims to enroll 444 participants and will track cancer recurrence and survival over three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HLX10 (an immunotherapy drug), capecitabine, oxaliplatin, and radiotherapy
- What this could lead to
- If successful, this could lead to a more effective treatment approach for locally advanced rectal cancer, potentially improving survival and reducing recurrence.
- What could go wrong
- This is a large phase 3 trial, but results are not guaranteed. Immunotherapy can cause immune-related side effects, and the best radiotherapy schedule is still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Which rectal cancer surgery preserves quality of life better? a study investigates
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- Can AI learn to grade endoscopy quality from video?
- Can precision protons spare rectal cancer patients from harsh side effects?
- A new radiation combo may spare the rectum in early cancer